Table .
Baseline Characteristics of Patients Presenting With STEMI
| Baseline characteristics | Total patient cohort (N=25) | Resilient cohort (n=14) | Vulnerable cohort (n=11) | P value |
|---|---|---|---|---|
| Age, y | 65±10 | 62±12 | 68±8 | 0.27 |
| Women, % | 44 | 43 | 45 | 0.99 |
| Total ischemic time, h | 6.7±4.1 | 6.6±4.4 | 6.9±3.7 | 0.85 |
| STEMI of LAD, % | 64 | 57 | 73 | 0.74 |
| Troponin T, ng/mL | 8.2±7.5 | 6.3±6.4 | 10.6±8.4 | 0.52 |
| C‐reactive protein, mg/L | 23.0±46.5 | 29.6±58.3 | 15.7±30.2 | 0.99 |
| WBC, cells/μL | 13 042±5077 | 12 856±5254 | 13 279±5087 | 0.99 |
| Past family history CAD, % | 6 | 5 | 1 | 0.27 |
| Smoking, % | 7 | 5 | 2 | 0.62 |
| Diabetes, % | 4 | 2 | 2 | 0.97 |
| Hypercholesterolemia, % | 12 | 7 | 5 | 0.97 |
| BMI, kg/m2 | 26.4±4.5 | 26.8±5.9 | 26.0±3.2 | 0.95 |
| Statin, % | 16 | 9 | 7 | 0.79 |
| β Blocker, % | 13 | 8 | 5 | 0.99 |
| Ca2+ channel blocker, % | 1 | 0 | 1 | 0.38 |
| ACEi, % | 15 | 9 | 6 | 0.99 |
| ARB, % | 2 | 2 | 0 | 0.35 |
| Aspirin, % | 15 | 9 | 6 | 0.99 |
| NYHA score, median | 1 | 1 | 1 | 0.89 |
ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; LAD, left anterior descending artery; NYHA, New York Heart Association; STEMI, ST‐segment–elevation myocardial infarction; and WBC, white blood cell count.